<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132495</url>
  </required_header>
  <id_info>
    <org_study_id>0904</org_study_id>
    <nct_id>NCT01132495</nct_id>
  </id_info>
  <brief_title>FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT</brief_title>
  <official_title>Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and
      cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in
      patients with stable coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, multi-national, multi-continental, randomized clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Event Rate (MACE)</measure>
    <time_frame>24 Month</time_frame>
    <description>MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall MACE</measure>
    <time_frame>5 years</time_frame>
    <description>Non-urgent revascularization procedures, cost and cost effectiveness, functional class, number of anti-anginal medication, rate of non-urgent revascularization, and rate of cerebrovascular event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1170</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A: PCI plus OMT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PCI plus optimal medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: OMT alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Optimal medical treatment alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FFR &gt; 0.80; treatment according to local practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stenting plus OMT</intervention_name>
    <description>FFR guided PCI, plus OMT</description>
    <arm_group_label>Cohort A: PCI plus OMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OMT</intervention_name>
    <description>OMT alone</description>
    <arm_group_label>Cohort A: OMT alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>FFR &gt; 0.80; treatment according to local practice</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with

               -  stable angina or,

               -  stabilized angina pectoris or,

               -  atypical chest pain or no chest pain but with documented silent ischemia

          2. at least one stenosis is present of at least 50% in one major native epicardial
             coronary artery and supplying viable myocardium

          3. Eligible for PCI

          4. Signed written informed consent

        Exclusion Criteria:

          1. Patients in whom the preferred treatment is CABG

          2. Patients with left main coronary artery disease requiring revascularization

          3. Patients with a recent STEMI or Non-STEMI

          4. Prior CABG

          5. Contra-indication to dual antiplatelet therapy

          6. LVEF &lt; 30%

          7. Severe LV hypertrophy

          8. Planned need for concomitant cardiac surgery

          9. Extremely tortuous or calcified coronary arteries precluding FFR measurements

         10. A life expectancy of less than 2 years

         11. Age under 21
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard De Bruyne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>O.L.Vrouwzlekenhuis Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Cardiology Associates</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk University and University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Praha</city>
        <zip>150 16</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <zip>1086</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria de Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina-Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orebro University Hospital</name>
      <address>
        <city>Orebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodersjukhuset AB</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Heart Centre</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>June 8, 2016</results_first_submitted>
  <results_first_submitted_qc>October 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable angina</keyword>
  <keyword>angina pectoris</keyword>
  <keyword>PCI</keyword>
  <keyword>FAME</keyword>
  <keyword>FAME II</keyword>
  <keyword>FFR</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Pressure wire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized to Cohort A if at least one stenoses had an FFR value of &lt;=0.80. Participants with FFR &gt;0.80 were treated according to local practice and were randomized to study follow-up / no study follow-up in Cohort B. Therefore, participants are either in cohort A or cohort B (not both).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A - PCI Plus OMT</title>
          <description>PCI plus optimal medical treatment
Stenting plus OMT: FFR guided PCI, plus OMT</description>
        </group>
        <group group_id="P2">
          <title>Cohort A - OMT Alone</title>
          <description>Optimal medical treatment alone
Standard of care: OMT alone</description>
        </group>
        <group group_id="P3">
          <title>Cohort B - Follow-up</title>
          <description>Observation with treatment based on physician preference</description>
        </group>
        <group group_id="P4">
          <title>Cohort B - No Follow-up Re-consented</title>
          <description>Observation with treatment based on physician preference, initially randomized to no follow-up, re-consented per safety data</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="447"/>
                <participants group_id="P2" count="441"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="407"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Various reasons</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A - PCI Plus OMT</title>
          <description>PCI plus optimal medical treatment
Stenting plus OMT: FFR guided PCI, plus OMT</description>
        </group>
        <group group_id="B2">
          <title>Cohort A - OMT Alone</title>
          <description>Optimal medical treatment alone
Standard of care: OMT alone</description>
        </group>
        <group group_id="B3">
          <title>Cohort B - Follow-up</title>
          <description>Observation with treatment based on physician preference</description>
        </group>
        <group group_id="B4">
          <title>Cohort B - No Follow-up Re-consented</title>
          <description>Observation with treatment based on physician preference, initially randomized to no follow-up, re-consented per safety data</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="447"/>
            <count group_id="B2" value="441"/>
            <count group_id="B3" value="166"/>
            <count group_id="B4" value="116"/>
            <count group_id="B5" value="1170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="9.3"/>
                    <measurement group_id="B2" value="63.9" spread="9.6"/>
                    <measurement group_id="B3" value="63.6" spread="9.8"/>
                    <measurement group_id="B4" value="64.4" spread="8.8"/>
                    <measurement group_id="B5" value="63.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="286"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Event Rate (MACE)</title>
        <description>MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization.</description>
        <time_frame>24 Month</time_frame>
        <population>The primary outcome analysis was designed for Cohort A only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - PCI Plus OMT</title>
            <description>PCI plus optimal medical treatment - Stenting plus OMT: FFR guided PCI, plus OMT</description>
          </group>
          <group group_id="O2">
            <title>Cohort A - OMT Alone</title>
            <description>Optimal medical treatment alone - Standard of care: OMT alone</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event Rate (MACE)</title>
          <description>MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization.</description>
          <population>The primary outcome analysis was designed for Cohort A only.</population>
          <units>percentage of subjects with SAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="441"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non Urgent Revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death or Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned Hospitalizations with urgent revasc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebrovascular Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Serious Adverse Event (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall MACE</title>
        <description>Non-urgent revascularization procedures, cost and cost effectiveness, functional class, number of anti-anginal medication, rate of non-urgent revascularization, and rate of cerebrovascular event.</description>
        <time_frame>5 years</time_frame>
        <posting_date>03/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unanticipated adverse device effects (UADE), major adverse cardiac event (MACE), serious adverse event (SAE) and stent thrombosis will be monitored through subject withdrawal following 3 year study follow-up.</time_frame>
      <desc>Only Serious Adverse Events were collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A - PCI Plus OMT</title>
          <description>PCI plus optimal medical treatment
Stenting plus OMT: FFR guided PCI, plus OMT</description>
        </group>
        <group group_id="E2">
          <title>Cohort A - OMT Alone</title>
          <description>Optimal medical treatment alone
Standard of care: OMT alone</description>
        </group>
        <group group_id="E3">
          <title>Cohort B - Follow-up</title>
          <description>Observation with treatment based on physician preference</description>
        </group>
        <group group_id="E4">
          <title>Cohort B - No Follow-up Re-consented</title>
          <description>Observation with treatment based on physician preference, initially randomized to no follow-up, re-consented per safety data</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="447"/>
                <counts group_id="E2" subjects_affected="324" subjects_at_risk="441"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="166"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death or MI</sub_title>
                <counts group_id="E1" events="48" subjects_affected="42" subjects_at_risk="447"/>
                <counts group_id="E2" events="65" subjects_affected="54" subjects_at_risk="441"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="166"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="447"/>
                <counts group_id="E2" events="48" subjects_affected="41" subjects_at_risk="441"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="447"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="441"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Event</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="447"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="441"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Other SAE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="447"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="441"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Non Urgent Revacularization</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="447"/>
                <counts group_id="E2" events="162" subjects_affected="144" subjects_at_risk="441"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="166"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Unplanned Hospitalization with Urgent Revascularization</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="447"/>
                <counts group_id="E2" events="63" subjects_affected="59" subjects_at_risk="441"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director, Global Clinical Affairs</name_or_title>
      <organization>St. Jude Medical</organization>
      <phone>651-756-5586</phone>
      <email>jmifek@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

